July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
59 citations,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
4 citations,
January 2018 in “Elsevier eBooks” Hormones are crucial for regulating body functions and imbalances can lead to health issues.
August 2024 in “Nutrition Bulletin” GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
4 citations,
January 2019 in “Therapeutic Advances in Endocrinology and Metabolism” Medications for PCOS don't seem to raise heart disease risk.